Skip to main content
. 2021 Sep 6;12:735260. doi: 10.3389/fphar.2021.735260

TABLE 3.

Polymorphisms of DILI-related transporter genes identified in GWAS and CGS.

Genes Drug Method Cohort OR P 95%Cl
ABCB1 rs1045642 (3435C→T) Nevirapine CGS 9 cases, 49 P (American) Ritchie et al. (2006) 0.254 0.021 0.09–0.76
ABCB1 rs2032582 Nevirapine 30 cases, 414 P (Japanese) Fukunaga et al. (2016) 2.59 6.8 × 10−4 1.49–4.56
ABCC2 rs717620 (24C→T) Diclofenac 24 cases, 48 T, 112 P (English) Daly et al. (2007) C vs. PC: 6.3 C vs. PC: 2*10−4 C vs. PC: 2.38–16.7
C vs. T: 5.0 C vs. T: 0.005 C vs. T: 1.71–14.7
SLCO1B1 rs4149056 HD-MTX 105 cases Yang et al. (2017) U 0.025 U
SLCO1B1*1a (388A/521T) Methimazole 44 cases, 118 P (Chinese) Jin et al. (2019) 2.21 0.023 1.11–4.39
SLCO1B1*1b (388G/521T) Methimazole 44 cases, 118 P (Chinese) Jin et al. (2019) 0.52 0.028 0.29–0.93
SLCO1B1*15 Rifampicin 118 cases, 155 P (Chinese) Li et al. (2012) 2.04 0.03 1.05–3.96
SLCO1B1*15 Bosentan 9 cases, 14 P Roustit et al. (2014) U 0.66 U

OR, odds ratio; P, p value; 95%CI, 95% confidence interval; C, medication with adverse reactions; T, medication with no adverse reactions; PC, population control; U, unknown.